Dr. Alemany is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2501 N Orange Ave
Ste 689
Orlando, FL 32804Phone+1 407-303-2024Fax+1 407-303-2038
Summary
- Dr. Carlos Alemany is an oncologist in Orlando, FL and is affiliated with AdventHealth Orlando. He received his medical degree from Ponce Health Sciences University and has been in practice 20 years. He also speaks multiple languages, including Spanish. He specializes in breast cancer, genitourinary oncology, and hematologic oncology and is experienced in breast cancer, prostate cancer, kidney cancer, bladder cancer, and testicular cancer. He has more than 25 publications and over 450 citings.
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2001 - 2004- Cleveland Clinic FoundationResidency, Internal Medicine, 1998 - 2001
Ponce Health Sciences University School of MedicineClass of 1998
Certifications & Licensure
FL State Medical License 2004 - 2026
OH State Medical License 2000 - 2005
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Alpha Omega Alpha 1997
Clinical Trials
- Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
- Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery Start of enrollment: 2013 Aug 01
- Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer Start of enrollment: 2013 Dec 17
- Join now to see all
Publications & Presentations
PubMed
- 60 citationsLenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, ran...Toni K Choueiri, Masatoshi Eto, Robert Motzer, Ugo De Giorgi, Tomas Buchler
The Lancet. Oncology. 2023-03-01 - 3 citationsChaperonin containing TCP1 as a marker for identification of circulating tumor cells in blood.Amanda Cox, Ana Martini, Heba Ghozlan, Rebecca Moroose, Xiang Zhu
Plos One. 2022-01-01 - 13 citationsEfficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.Denise A. Yardley, Lowell L. Hart, Anne Favret, Sibel Blau, Sami Diab
Clinical Breast Cancer. 2019-02-28
Committees
- Director, Protocol Review Comittee 2017 - Present
Research History
- Director of Clinical Research, AdventHealth Cancer Institute Orlando2016 - Present
Professional Memberships
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
